Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine

Circulation

Volumn 108, Issue 13, 2003, Pages 1575-1580

  Holden, Desmond P ^a   Cartwright, Judith E ^b   Nussey, Stephen S ^c   Whitley, Guy St J ^b  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Cardiovascular diseases; Endothelium; Nitric oxide

Indexed keywords

DIMETHYLARGININASE; ESTRADIOL; ESTROGEN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; AMINO ACID METABOLISM; ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

AMIDOHYDROLASES; ARGININE; CARDIOTONIC AGENTS; CELL LINE; DRUG IMPLANTS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0141618308     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000091083.61609.DF     Document Type: Article

References (36)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288: 321-333.
4. Gray GA, Sharif I, Webb DJ, et al. Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends Pharmacol Sci. 2001;22:152-156.
5. Mendelsohn ME. Nongenomic E. R-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res. 2000;87: 956-960.
6. Binko J, Majewski H. 17 beta-estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol. 1998;43: H853-H859.
7. Vanburen GA, Yang DS, Clark KE. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl-ester, an inhibitor of nitric-oxide synthesis. Am J Obstet Gynecol. 1992;167:828-833.
8. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA. 2003;100:4807-4812.
9. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
10. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem. 2003;278:2118-2123.
11. MacAllister RJ, Whitley GS, Parry H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;117:P76-P76.
12. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339: 572-575.
13. Bode-Boger SM, Boger RH, Kienke S, et al. Elevated L-arginine/ dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arganine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996;219:598-603.
14. Maxwell AJ, Cooke JP. The role of nitric oxide in atherosclerosis. Coron Artery Dis. 1999;10:277-286.
15. Holden DP, Fickling SA, Whitley GS, et al. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998;178:551-556.
16. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77:808-813.
17. MacAllister RJ, Pany H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119: 1533-1540.
18. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209-214.
19. Fickling SA, Tooze JA, Whitley GS. Characterization of human umbilical vein endothelial-cell fines produced by transfection with the early region of Sv40. Exp Cell Res. 1992;201:517-521.
20. Achan V, Tran CT, Arrigoni F, et al. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res. 2002;90: 764-769.
21. Macallister RJ, Fickling SA, Whitley GS, et al. Metabolism of methylarginines by human vasculature: implications for the regulation of nitric-oxide synthesis. Br J Pharmacol. 1994;112;43-48.
22. Williams RL, Risau W, Zerwes HG, et al. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell. 1989;57:1053-1063.
23. Kimoto M, Tsuji H, Ogawa T, et al. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys. 1993;300:657-662.
24. Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16:309-314.
25. Fickling SA, Holden DP, Cartwright JE, et al. Regulation of macrophage nitric oxide synthesis by endothelial cells: a role for N-G,N-G-dimethylarginine. Acta Physiol Scand. 1999;167:145-150.
26. Bogle RG, Macallister RJ, Whitley GS, et al. Induction of N-G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases. Am J Physiol. 1995;38:C750-C756.
27. Tsikas D, Boger RH, Sandmann J, et al. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 2000;478:1-3.
28. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
29. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146.
30. Rosselli M, Imthurm B, Macas E, et al. Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol mediated NO release. Biochem Biophys Res Commun. 1994:202:1543-1552.
31. Cicinelli E, Ignaro LJ, Matteo MG, et al. Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol. 1999;180:334-339.
32. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric-oxide synthases by sex-hormones. Proc Natl Acad Sci U S A. 1994;91: 5212-5216.
33. Teerlink T, Neele SJ, De Jong S, et al. Oestrogen replacement therapy lowers plasma levels of asymmetric dimethylarginine in healthy postmenopausal women. Clin Sci. 2003;105:67-71.
34. Stefano GB, Prevot V, Beauvillain JC, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation. 2000;101:1594-1597.
35. Baum M. Tamoxifen: the treatment of choice. Why look for alternatives? Br J Cancer. 1998;78:1-4.
36. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992.